Skip to content

葛兰素史克

US · GSK #230 按市值排名 上市于 1970
49.51 +0.49 +1.00%
实时 - 追踪5344个代码 - 心跳于248秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
30.21 合理价值 ≈ 51.12 72.04
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为30.21-72.04。
  • 当前价格比按平均倍数计算的合理价值(51.12)低3.2%。

估值 各估值倍数与自身5年区间的对比

市净率 4.00 低于历史水平 第12百分位
5年平均 4.70 · 在Drug Manufacturers - General中排名第8/18
市盈率 14.94 处于历史正常水平 第52百分位
5年平均 13.87 · 前瞻 12.37 · 在Drug Manufacturers - General中排名第4/15
市销率 2.12 处于历史正常水平 第56百分位
5年平均 2.06 · 前瞻 2.03 · 在Drug Manufacturers - General中排名第6/18

同业对比 Drug Manufacturers - General

公司 市值 市盈率(TTM) 市净率 股息率
葛兰素史克 (GSK) 99.19B 15.83 4.23 3.58%
Eli Lilly and Co (LLY) 1.18T 42.20 34.93 0.51%
Johnson & Johnson (JNJ) 615.87B 38.84 7.25 2.07%
AbbVie (ABBV) 504.37B 80.63 -84.97 2.36%
Merck & Co (MRK) 360.08B 116.76 8.59 2.30%
Novartis AG (NVS) 286.29B 22.75 6.89 3.15%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值49.34 经济护城河Wide 不确定性Medium

当前股价高于晨星合理价值估算0.3%。

合理价值

GSK PLC earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% discount to our quantitative fair value estimate of $49.34 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's profitability increases our fair value estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 9.8% ranks in the top 20% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.

Alternatively, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 24.7%, for example, lies in the bottom 30% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

The company earns a quantitative moat rating of wide, suggesting a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

葛兰素史克 讨论区 0 条评论

发表评论